Kieran Jennifer A, O'Reilly Eimear, O'Dea Siobhan, Bergin Colm, O'Leary Aisling
1 Department of Genitourinary Medicine and Infectious Disease, St James Hospital, Dublin, Ireland.
2 National Centre for Pharmacoeconomics, St James Hospital, Dublin, Ireland.
Int J STD AIDS. 2017 Oct;28(12):1239-1246. doi: 10.1177/0956462417696215. Epub 2017 Mar 2.
There is interest in introducing generic antiretroviral drugs (ARVs) into high-income countries in order to maximise efficiency in health care budgets. Studies examining patients' and providers' knowledge and attitudes to generic substitution in HIV are few. This was a cross-sectional, observational study with a convenience sample of adult HIV-infected patients and health care providers (HCPs). Data on demographics, knowledge of generic medicine and facilitators of generic substitution were collected. Descriptive and univariate analysis was performed using SPSS V.23™. Questionnaires were completed by 66 patients. Seventy-one per cent would have no concerns with the introduction of generic ARVs. An increase in frequency of administration (61%) or pill burden (53%) would make patients less likely to accept generic ARVs. There were 30 respondents to the HCP survey. Concerns included the supply chain of generics, loss of fixed dose combinations, adherence and use of older medications. An increase in dosing frequency (76%) or an increase in pill burden (50%) would make HCPs less likely to prescribe a generic ARV. The main perceived advantage was financial. Generic substitution of ARVs would be acceptable to the majority of patients and HCPs. Reinvesting savings back into HIV services would facilitate the success of such a programme.
为了使医疗保健预算的效率最大化,人们对将通用抗逆转录病毒药物(ARV)引入高收入国家感兴趣。关于患者和医疗服务提供者对HIV治疗中通用药物替代的知识及态度的研究较少。这是一项横断面观察性研究,采用便利抽样法选取成年HIV感染患者和医疗服务提供者(HCP)作为样本。收集了有关人口统计学、通用药物知识以及通用药物替代促进因素的数据。使用SPSS V.23™进行描述性和单变量分析。66名患者完成了问卷调查。71%的患者对引入通用抗逆转录病毒药物没有顾虑。给药频率增加(61%)或药丸负担增加(53%)会使患者接受通用抗逆转录病毒药物的可能性降低。HCP调查有30名受访者。顾虑包括通用药物的供应链、固定剂量组合的缺失、依从性以及使用较老的药物。给药频率增加(76%)或药丸负担增加(50%)会使HCP开具通用抗逆转录病毒药物的可能性降低。主要的可感知优势是经济方面的。抗逆转录病毒药物的通用药物替代对大多数患者和HCP来说是可以接受的。将节省的资金重新投入到HIV服务中,将有助于该计划的成功实施。